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Abstract
Summary Vertebral fractures are a major adverse conse-
quence of osteoporosis. In a large placebo-controlled trial in
postmenopausal women with osteoporosis, strontium rane-
late reduced vertebral fracture risk by 33% over 4 years,
confirming the role of strontium ranelate as an effective
long-term treatment in osteoporosis.
Introduction Osteoporotic vertebral fractures are associated
with increased mortality, morbidity, and loss of quality-of-
life (QoL). Strontium ranelate (2 g/day) was shown to
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4020 Liège, Belgiumprevent bone loss, increase bone strength, and reduce
vertebral and peripheral fractures. The preplanned aim of
this study was to evaluate long-term efficacy and safety of
strontium ranelate.
Methods A total of 1,649 postmenopausal osteoporotic
women were randomized to strontium ranelate or placebo
for 4 years, followed by a 1-year treatment-switch period
for half of the patients. Primary efficacy criterion was
incidence of patients with new vertebral fractures over
4 years. Lumbar bone mineral density (BMD) and QoL
were also evaluated.
Results Over 4 years, risk of vertebral fracture was reduced
by 33% with strontium ranelate (risk reduction=0.67, p<
0.001). Among patients with two or more prevalent
vertebral fractures, risk reduction was 36% (p<0.001).
QoL, assessed by the QUALIOST®, was significantly
better (p=0.025), and patients without back pain were
greater (p=0.005) with strontium ranelate than placebo over
4 years. Lumbar BMD increased over 5 years in patients
who continued with strontium ranelate, while it decreased
in patients who switched to placebo. Emergent adverse
events were similar between groups.
Conclusion In this 4- and 5-year study, strontium ranelate
is an effective and safe treatment for long-term treatment of
osteoporosis in postmenopausal women.
Keywords Bonedensitometry.Menopause.Osteoporotic
fracture.Osteoporosistreatment.Strontiumranelate
Introduction
Vertebral fractures are one major adverse clinical con-
sequences of osteoporosis [1]. Most vertebral fractures are
precipitated by everyday activities rather than falls [2], and
occurrence of a vertebral fracture is a powerful risk factor
for future fractures [3]. Vertebral fractures are associated
with increased mortality, long-term morbidity [4], and
considerable health care costs [5] that are predicted to
increase markedly over the period to 2020 [6].
Vertebral fractures, even those not recognized clinically,
are also associated with substantial back pain and function-
al limitation [7, 8] and significant loss of quality-of-life
(QoL). Both mental and physical domains of quality of life
may be affected, and impairment is directly related to both
severity and number of fractures [9, 10].
Strontium ranelate is an oral anti-osteoporotic drug that
has been shown to prevent bone loss and increase bone
strength in experimental studies [11]. Strontium ranelate
increased bone formation in vitro, enhancing pre-osteoblas-
tic cell replication and osteoblastic differentiation and
decreasing abilities of osteoblasts to induce osteoclasto-
genesis via the calcium-sensing receptor (CaR) and an
increase in the OPG/RANKL ratio [12]. In postmenopausal
women with osteoporosis, strontium ranelate 2 g/day
increased bone mineral density (BMD) in a placebo-
controlled, 2-year dose–response study in 353 patients
[13]. The Spinal Osteoporosis Therapeutic Intervention
(SOTI) trial was designed to evaluate efficacy of strontium
ranelate (2 g/day) in reducing vertebral fractures. Over the
first year and first 3 years of treatment, strontium ranelate
treatment was associated with reductions of 49% (p<0.001)
and 41% (p<0.001), respectively, relative to placebo, in the
risk of vertebral fractures [14].
Strontium ranelate has also shown significant efficacy
against peripheral fractures and hip fractures in patient at
risk over 3 years [15] and 5 years [16]. The purpose of the
present article is to present results from the SOTI trial
relating to vertebral fracture risk, changes in BMD and QoL
for the 4-year initial treatment period, and also BMD results
from the fifth-year treatment-switch period.
Methods
Patients
Post-menopausal (≥5 years) women were ambulatory
Caucasian, ≥50 years of age with at least one prevalent
osteoporotic vertebral fracture. Mean lumbar BMD had to
be ≤0.840 g/cm
2 [17]. Exclusion criteria were described
elsewhere [18] and were mainly concomitant pathologies or
treatment potentially interfering with bone metabolism.
Study design
Methodological details have been described previously
[18]. In brief, this was an international, randomized,
double-blind, placebo-controlled trial. Previous to and
during the study, patients were supplemented in vitamin D
and calcium according to their need [18].
Patients were randomized (1:1) to receive strontium
ranelate 2 g/day or placebo orally for 4 years, followed by a
1-year period in which patients in the strontium ranelate
group were randomized either to switch to placebo (50%,
SR/placebo group) or to continue on strontium ranelate 2 g/
day (50%, SR/SR group), while all patients in the placebo
group were switched to strontium ranelate 2 g/day (placebo/
SR group; Fig. 1).
Outcome measures
For the 4-year treatment period, the pre-planned primary
efficacy criterion was the incidence of patients experiencing a
new vertebral fracture. Secondary criteria included new
clinical vertebral fractures, osteoporotic peripheral fractures,
1664 Osteoporos Int (2009) 20:1663–1673changes in body height, L2–L4BMD, total hip and femoral
neck BMD, bone turnover markers, and quality-of-life.
For the fifth-year treatment-switch period, the primary
efficacy criterion was L2–L4BMD. Secondary criteria in-
cluded total hip and femoral neck BMD, new vertebral
fractures, and bone turnover markers.
Vertebral fractures were determined from radiographs
taken at baseline (M0) and annually thereafter. Radiographs
were analyzed semi-quantitatively [19], with a new verte-
bral fracture defined as a change from grade 0 to grade 1 or
higher [19]. Clinical vertebral fractures were defined as new
or worsening fractures with back pain and/or body height
loss of ≥1 cm. Radiographs were assessed centrally
(CEMO, France; Pr C. Roux).
Peripheral osteoporotic fractures were determined by
investigators from radiographs or hospital reports [20].
Standing body height was standardized and measured by
Harpenden stadiometer at all visits.
Total hip, femoral neck, and lumbar BMD were
measured by dual-energy X-ray absorptiometry (DXA)
using Hologic devices at baseline and every 6 months
post-baseline. A cross-calibration program was per-
formed throughout the study [21], and all scans were
analyzed centrally. Strontium distributes in bone and
absorbs X-rays to a greater extent than calcium. The
presence of strontium may account for approximately 50%
of BMD increases measured by DXA with strontium
ranelate treatment [22].
Bone turnover markers were assessed at baseline, after 3
and 6 months of treatment, and then annually during
4 years; during the fifth year, they were assessed only in
patients treated for 4 years with strontium ranelate and after
51 and 60 months of treatment. Bone alkaline phosphatase
(bALP) was assayed by immunoradiometric assay (Tan-
dem®-R Ostase®, Beckman Coulter, formerly Hybritech,
San Diego, CA, USA), and serum C-telopeptide cross-link
of type I collagen (sCTX) was assayed using an enzyme-
linked immunosorbent assay (serum CrossLaps®ELISA—
Nordic Bioscience Diagnostic, formerly Osteometer Bio-
Tech, Herlev, Denmark).
Parathyroid hormone was assessed with an immunor-
adiometric assay (N-tact®PTH SP IRMA, Diasorin, USA).
* of randomized population at M0
Patients randomized at M0 (n = 1649) 
Strontium ranelate 
 n = 828 
Placebo 
n = 821 
Completed to  M48 
n = 572 
Completed to M48 
n = 577 
Intent to treat population M48 
n = 719, [86.8%*] 
Intent to treat population M48 
 n = 726, [88.4%*] 
Randomized at M48 
 n = 572
Switched at M48  
n = 577 
Continued strontium ranelate 
(SR/SR group) 
n = 288 
Switched to strontium ranelate 
(Placebo/SR group) 
n = 577 
Switched to placebo 
(SR/placebo group)  
n = 284 
Completed to M60 
n = 261 
Completed to M60 
 n = 544 
Completed to M60 
 n = 265 
Intent to treat population M60 
  n = 221 [76.7%**] 
Intent to treat population M60  
n = 434 [75.2%**] 
Intent to treat population M60  
n = 225 [79.2%**] 
** of randomized population at M48
Fig. 1 Flow of patients through
the study
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naires: the Short-Form 36 (SF-36®), a widely used generic
36-item instrument [23], and QUALIOST®, a disease-
specific 23-item instrument designed to complement the
SF-36® in postmenopausal patients with vertebral osteopo-
rosis [24]. Both questionnaires were completed every
6 months throughout the trial. In the SF-36®, items are
grouped into eight dimensions, which were further com-
bined into summary scores for mental and physical
components. In each case, scores range from 0 to 100,
with higher scores indicating better QoL. QUALIOST®
contains two dimensions, physical (10 items) and emotional
(13 items). Scores again range from 0 to 100, higher scores
indicate greater impairment of QoL. One QUALIOST®
item (physical dimension item 6) relates specifically to back
pain. The QUALIOST® cross-cultural validity and respon-
siveness have been validated using earlier (3-year) data
from the present (SOTI) trial [25].
Statistical analysis
Randomized assignment of treatment was stratified by
country and performed using permutation blocks with a
fixed size of four.
All these pre-planned efficacy analyses were performed
in accordance with the intention-to-treat (ITT) principle. For
the M0–M48 period, ITT population for fracture incidence
analysis was defined as all randomized patients who took at
least one sachet of study drug and with (at least two) X-ray
assessments between M0 and M48. For the M48–M60
period, ITT population was defined as all patients who
performed the M48 visit, took at least one sachet of study
drug between M0 and M48 and after M48, with validated L2–
L4DXA measurements at M0 and M48, and post M48. The
ITT population for QoL analysis comprised patients from
the ITT population who had at least one assessable SF-36®
(i.e., <50% missing data) and one assessable QUALIOST®
completed at baseline, plus at least one assessable
SF36® and one assessable QUALIOST® completed post
baseline (>12 months, until 4 years of treatment).
For the 4-year analysis, the incidence over time of patients
with at least one new osteoporotic vertebral fracture and new
clinical vertebral fracture were analyzed by Kaplan–Meier
method. Analysis of osteoporosis-related vertebral fractures
wasthereforecarriedoutonallavailabledata(undertreatment
or not) up to the cutoff date of the new vertebral fracture,
whatever the date of the last study visit for the patients
considered. Consequently, as the population selection bias
phenomenon increases year after year, any isolated yearly
statistical comparison regarding fracture occurrence would
provide biased (as well as inaccurate) estimates and would
lead to misleading clinical interpretation. Therefore, treatment
groups were compared using the Cox model over 4 years.
The incidence of vertebral fractures was adjusted for age,
country, prevalent vertebral fractures, and L2–L4BMD and
incidence of non-vertebral fractures was adjusted for age,
country, body mass index, and femoral neck BMD. A log-
rank non-parametric test was used to confirm results of the
Cox model. Between-group comparisons of BMD and bone
markers were performed using covariance analysis with
baseline value as covariate and two-tailed Student’s t tests.
Between-group comparison of body height was performed
on the change from baseline using a covariance analysis
adjusted on height at baseline and prevalent vertebral
fracture. The number of patients in each group with a body
height loss of ≥1 cm was compared using the chi-squared
test.
For the fifth-year treatment-switch period (M48 to M60),
annual incidence of new vertebral fracture was estimated
using a within-group 95% confidence interval of the
estimates with Kaplan–Meier method. Within-group com-
parisons of BMD were performed using the Student’s t test
for paired samples and between-group comparisons using
the same test for independent samples. Bone markers were
analyzed using descriptive statistics. At entry in the fifth
year, a between-group comparison on BMD (lumbar and
femoral neck level) and on corresponding T scores was
performed using a two-sided Student’s t test for indepen-
dent samples.
Between-group comparisons of the SF-36® and QUAL-
IOST® total and component scores at each time point were
performed using a repeated-measures analysis (mixed
model), followed, in the case of non-significant treat-
ment×time interaction, by Fisher’s test. Analysis was first
performed on raw data and confirmed by repeating with
imputation of missing data. Missing data were replaced,
taking into account fracture status of each patient. For
example, for patients who had experienced a fracture and
for whom the questionnaire was missing after they had their
fracture, the average change in score seen in patients after
they experienced a fracture was added to the last available
score for that patient. Missing items within questionnaires
had already been taken into account when calculating
scores, with dimension scores being calculated as the mean
of non-missing items only if at least half of the items in that
dimension had been answered. An analysis of covariance
(ANCOVA), with baseline score as covariate, was per-
formed to compare between groups the changes between
baseline and last value and between baseline and last value
on treatment. The number of patients free from back pain
(QUALIOST® item 6) in each group was compared using
Poisson regression.
The type I error rate was set at 5% throughout.
Statistical analyses were performed by Servier, and the
study was organized under the control of independent
advisory and steering committees.
1666 Osteoporos Int (2009) 20:1663–1673Safety evaluation
Adverse events reported spontaneously by patients or
elicited during interview were recorded at each study visit.
Blood and urinary calcium and blood phosphorus were
assessed at each visit. Hematology and biochemistry tests
were performed at M0, M6, M12, and then annually.
Adverse events were reviewed by a safety committee,
independent from the sponsor and from the other study
committees.
Results
Patients
A total of 1,649 patients were randomized: 828 to strontium
ranelate and 821 to placebo. Of these, 1,149 patients
(69.7%) completed the 4-year treatment period (strontium
ranelate, 572 patients; placebo, 577 patients) and entered
the fifth-year treatment-switch period. All placebo-treated
patients were switched to strontium ranelate, and strontium
ranelate-treated patients were randomized either to continue
with strontium ranelate (SR/SR group, n=288) or to switch
to placebo (SR/placebo group, n=284; Fig. 1). The propor-
tion of randomized patients included in the ITT population at
M48 was 87.6%. At M60, 1,070 patients completed the
study; however, 880 patients, representing 76.6% of those
who entered the fifth year, were included in the ITT
population at M60. The reasons for exclusion of these 190
patients were absence of treatment from M48 and absence of
assessable lumbar BMD at baseline, M48, or after M48.
Demographic and clinical characteristics of randomized
patients are shown in Table 1. There were no relevant
between-group differences. At entry to the fifth-year
treatment-switch period, BMD values and corresponding
T-scores were lower in patients on placebo during the 4-
year treatment period. In addition, a slight between-group
difference was observed for patients having taken concom-
itant treatment for osteoporosis during the study (4.2% and
2.1% patients in the SR/SR and SR/placebo groups versus
6.4% in the placebo/SR group). No other relevant between-
group differences were observed for the remaining baseline
characteristics.
Efficacy
Vertebral fractures and BMD
Four-year treatment period The risk of new vertebral
fracture over the M0 to M48 period was reduced by 33%
with strontium ranelate, relative to placebo [risk reduction
(RR), 0.67; 95% CI (0.55, 0.81), p<0.001]. The number of
patients needed to treat for 4 years to prevent one new
vertebral fracture was 11 [95% CI (7, 24)]. Among severely
affected patients (with two or more prevalent vertebral
fractures at baseline), risk reduction with strontium ranelate
was 36% (RR, 0.64; 95% CI (0.50, 0.81), p<0.001]. The
total number of new vertebral fractures was significantly
lower in the strontium ranelate group (275) than in the
placebo group (421; p<0.001). The risk of new clinical
vertebral fracture was reduced by 36% with strontium
ranelate relative to placebo [RR, 0.64; 95% CI (0.49, 0.83),
p<0.001] (Fig. 2).
Table 1 Baseline characteristics at year 0 and at year 4 of the M48 and M60 ITT populations, expressed as mean±standard deviation unless
otherwise stated
Year 0 Year 4
Strontium
ranelate, N=719
Placebo,
N=726
SR/SR,
N=221
SR/placebo,
N=225
Placebo/SR,
N=434
Age, years 69.4±7.2 69.3±7.3 72.1±6.9 72.1±6.7 72.1±6.9
Time since menopause (years) 22.1±8.8 21.7±8.8 24.5±8.5 25.0±8.7 24.3±8.3
One or more prevalent vertebral
fracture, n patients (%)
628 (87.5) 626 (86.3) 192 (86.9) 197 (87.6) 372 (86.1)
Number of prevalent vertebral
fractures
2.5±2.0 2.5±2.1 2.7±2.2 2.8±2.1 3.1±2.7
Lumbar BMD (g/cm
2) 0.731±0.125 0.720±0.118 0.849±0.158* 0.862±0.163* 0.717±0.127
Lumbar T-score −3.52±1.30 −3.64±1.23
Femoral neck BMD (g/cm
2) 0.591±0.086 0.590±0.093 0.655±0.888* 0.643±0.087* 0.581±0.094
Femoral neck T-score −2.78±0.77 −2.79±0.84
bALP (ng/mL) 12.3 ±4.5 12.8±4.9
sCTX (ng/mL) 0.51±0.24 0.52±0.24
*p<0.001 for the difference SR/SR–placebo/SR or SR/placebo–placebo/SR (two sided Student’s t test for independent samples)
Osteoporos Int (2009) 20:1663–1673 1667The risk of peripheral fracture was not significantly
different over 4 years between the two groups [RR=0.92,
95% CI (0.72, 1.19)].
Mean reduction in body height was less in the strontium
ranelate group compared with placebo [estimated between-
group difference (SE) (mm), 2.1 (0.8), p=0.007], and the
proportion of patients with a reduction in body height of
≥1 cm was significantly lower in the strontium ranelate
group (36.6%) than with placebo (42.1%; p=0.034).
BMD increased over time at all sites measured in the
strontium ranelate group but decreased slightly in the placebo
group. The between-group differences for the change from
baseline in BMD at the different sites were 14.6% for the
lumbar site, 8.7% for the femoral neck, and 9.8% for the total
hip site (p<0.001 for each site).
Serum concentration of bALP was higher in the strontium
ranelate group than in the placebo group from M3 to M48,
with significant between-group difference on the change from
baseline to end (change from baseline to end, 2.5±4.5 and
1.9±5.8 ng/mL in the strontium ranelate and placebo groups,
respectively; p=0.031). Concentration of sCTX was lower in
the strontium ranelate group than in the placebo group from
M3 to M48, with a significant between-group difference on
the change from baseline to end (change from baseline to
end, 0.01±0.30 and 0.06±0.27 ng/mL in the strontium
ranelate and placebo groups, respectively; p<0.001).
Fifth-year treatment period In the SR/SR group, the
progressive increase in L2–L4BMD seen throughout the
4 years of the trial continued during the fifth year, with a
further increase of 1.2±5.8% between M48 and end on
treatment (Fig. 3). In the SR/placebo group, the increase in
BMD began to reverse after the switch to placebo (−3.2±
5.8%) between M48 and end on treatment, although BMD
was still substantially higher at M60 (0.819±0.147 g/cm
2)
compared with M0 (0.734±0.123 g/cm
2). Both the increase
in L2-L4BMD in the SR/SR group and the decrease in the
SR/placebo group between M48 and end on treatment were
significant (p<0.001 and p=0.002, respectively). BMD in
the placebo/SR group increased after switch to strontium
ranelate; the increase between M48 and end on treatment
(5.3±7.3%) was similar to the increase seen in strontium
ranelate-treated patients during the first year (M0–M12) of
the trial (6.4±7.7%).
BMD changes at other measured sites were similar to those
at the L2–L4 site. Significant differences were seen in the
change in BMD between M48 and end over 5 years
between the SR/SR group and the SR/placebo group at each
site (p<0.001 in each case; Table 2).
The decrease in BMD in the SR/placebo group was not
associated with a significant between-group difference in the
incidence of new vertebral fractures over the fifth year of
treatment: 6.9% (14 patients) in the SR/SR group compared
with 8.9% (19 patients) in the SR/placebo group (p=0.463).
However, these results should be interpreted with caution
since the number of patients with a fracture is small.
Bone markers (fifth year) After discontinuation of treat-
ment, a significant decrease in bALP from M48 to last
observation on treatment (from 15.2±5.2 to 11.6±3.6 ng/
mL, p<0.001) and an increase in sCTX (from 0.552±0.263
to 0.588±0.225 ng/mL, p=0.038) were observed.
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1668 Osteoporos Int (2009) 20:1663–1673Quality of life (fourth year) Atotal of1,250patients(87%of
the ITT population) were assessed for QoL (strontium
ranelate n=623, placebo n=627). For the SF-36® question-
naire, there were no significant differences between the
treatment groups for the mental and physical component
summary scores. Among the individual SF-36® dimensions,
a significant between-group difference on the change from
baseline to last value and on the change from baseline to last
value on treatment was observed for the General Health
Perception dimension (p=0.043 and p=0.012, respectively).
QUALIOST® global scores were lower (indicating
better QoL) in the strontium ranelate group than in the
placebo group at each post-baseline assessment and
significant between-group differences in favor of strontium
ranelate in the change from baseline to endpoint (mean
change from baseline in the strontium ranelate group=
−0.06 and mean change from baseline in the placebo
group=1.92, p=0.020) and from baseline to endpoint on
treatment (mean change from baseline in the strontium
ranelate group=−0.40 and mean change from baseline in
the placebo group=1.63, p=0.015) were observed.
When the physical and emotional QUALIOST® dimen-
sions were considered separately, a statistically significant
between-group difference of the change from baseline to
last value and from baseline to last value in treatment in
favor of strontium ranelate was observed for both emotional
score (p=0.025 and p=0.012, respectively) and physical
score (p=0.022 and p=0.034, respectively; Fig. 4).
Proportion of patients free of back pain (patients who
answered ‘not at all’ to ‘Have you had pain in the middle or
upper part of your back?’, QUALIOST® item 6) after
4 years of treatment was 28% higher in the strontium
ranelate group than with placebo (p=0.005). Indeed, 14.6%
of patients receiving strontium ranelate versus 11.2% of
patients receiving placebo were free of back pain [RR, 1.28;
95% CI (1.08, 1.52)].
Safety
In all, over 4 years, 739 patients in the strontium ranelate
group (89.5%) and 720 patients in the placebo group
(88.5%) reported at least one emergent adverse event under
treatment. Diarrhea (6.3% versus 3.8%, respectively) and
nausea (5.2% versus 3.8%, respectively) were more
frequently reported in the strontium ranelate group than in
the placebo group. Skin disorders were reported similarly in
both groups (14.5% in the strontium ranelate group and
15.1% in the placebo group), including dermatitis and
eczema (2.1% versus 1.8% and 1.0% versus 1.2%,
respectively). Over 4 years, four serious adverse events in
each group concerning skin disorders were reported (one
dermatitis and one contusion in each group, a pemphigoid
and a lichen planus in the strontium ranelate group, and two
skin ulcers in the placebo group). None were considered as
related to the study drug by the investigators.
Over 4 years, the number of patients reporting an
embolism or a venous thrombosis was eight and five in
the strontium ranelate and placebo groups, respectively.
In the fifth year, in patients starting strontium ranelate
(placebo/SR group), the number of emergent adverse events
reported was similar to the SR/SR and SR/placebo groups
(55.7% versus 56.7% and 55.5%, respectively). Diarrhea,
nausea, and headache were more frequently reported. These
events occurred mainly during the first 3 months of
Table 2 Relative changes (%) in bone mineral density between M48 and last observation on treatment in patients continuing on strontium
ranelate (SR/SR group) and switching to placebo (SR/placebo group)
SR/SR group
(mean±SD), N=221
SR/placebo group
(mean±SD), N=225
Between-group
difference (SE)
a
95% CI p value
Lumbar L2–L4 1.21±5.78 (n=207) −3.22±5.79 (n=212) 4.43 (0.57) 3.32; 5.54 <0.001
Femoral neck 0.11±4.16 (n=199) −2.12±5.79 (n=207) 2.22 (0.50) 1.24; 3.21 <0.001
Total hip 0.41±3.02 (n=199) −2.53±4.36 (n=207) 2.94 (0.37) 2.21; 3.67 <0.001
aSR/SR group minus SR/placebo group
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Fig. 4 Changes from baseline to last evaluation (baseline–endpoint)
during the M0–M48 treatment period in quality of life assessed by
QUALIOST® global score, emotional score, and physical score in the
ITT population on treatment (ANCOVA). p value difference versus
the placebo group
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similarly in the three groups (5.5% in the SR/SR group,
7.3% in the SR/placebo group, and 4.3% in the placebo/SR
group). Two serious adverse events classified as skin
disorder occurred: one contusion due to a fall in the
placebo/SR group and one in the SR/placebo. None was
considered as related to the study drug.
Serum creatinine kinase concentrations increased in
some patients starting strontium ranelate. High levels
(concentration greater than three times the upper value of
the normal reference range) were detected in 0.7% of the
patients (three patients), but none reached five times the
upper value of the normal reference range.
Concerning calcium homeostasis, over 4 years, mild
decreases in calcium and parathyroid hormone (PTH)
serum levels were observed in the strontium ranelate group
(from 2.38±0.13 mmol/L at baseline to 2.22±0.10 mmol/L
at end and from 30.98±12.71 pg/mL at baseline to 28.75±
11.60 pg/mL at end, respectively), while blood phosphorus
concentration slightly increased (from 1.22±0.19 mmol/L
at baseline to 1.31±0.17 mmol/L at end). These changes
were of too small magnitude to have clinical relevance.
During the fifth year, in the group which stopped strontium
ranelate, trends to inverse changes were observed; slight
increase in serum calcium concentration (from 2.31±0.93
to 2.36±0.09 mmol/L) and decrease in blood phosphorus
concentration (1.31±0.16 to 1.22±0.14 mmol/L).
Discussion
The main result of this pre-planned analysis is that long-term
treatment (4 years) with strontium ranelate produced a
significant 33% reduction in the risk of vertebral fractures. A
similar reduction (36%) was seen in the subset of severely
affected patients with ≥2 prevalent vertebral fractures at
baseline. The reductions in fracture risk were associated with
a progressive increase in BMD of the lumbar and hip regions
that extended throughout the treatment period.
Few studies of anti-osteoporotic drugs using randomized
initial treatment periods of duration comparable to the
present trial (4 years) and in the same type of patients are
published. In patients without prevalent vertebral fracture,
alendronate (10 mg/day) reduced by 44% vertebral frac-
tures over 4 years, but no data were available in patients
with prevalent vertebral fracture [26]. Raloxifene reduced
vertebral fracture by 34% over 4 years in patients with
prevalent vertebral fracture [27]. The 33% risk reduction
seen over 4 years in this study is of similar magnitude to
these results. No data are available for risedronate for initial
randomized periods of 4 years or longer, but a reduction in
vertebral fractures of 59% was reported from a smaller (265
patients) 2-year extension to a 3-year study [28].
The reduction in risk of vertebral fractures of 33% over
4 years in the present study is smaller than that seen in the
corresponding analysis over 3 years (41%) [14]. An
apparent decrease in the size of risk reduction achieved
with greater treatment duration has been reported in
previous studies of other anti-osteoporotic drugs. For
risedronate, risk reductions of 65% and 61% seen at 1 year
decreased to 41% and 49%, respectively, over 3 years [29,
30]. Comparisons of cumulative endpoints at different
times during a long-term study must therefore be inter-
preted with caution. The patients at risk of a given
endpoint, although well balanced between treatment groups
in terms of disease characteristics and level of risk at
randomization, become progressively unbalanced (for ex-
ample, due to censoring of fracture cases, attrition of more
severely affected patients, and introduction of concomitant
osteoporosis medication) over time if treatments differ in
efficacy. Attrition of high-risk patients will be more rapid in
the low efficacy (generally placebo) group.
In the later parts of the study, therefore, the placebo
group will effectively contain fewer high-risk patients than
the active treatment group, and the effects of active
treatment will appear to be reduced.
The vertebral antifracture efficacy of strontium ranelate
over4yearsinthisstudyhas alsobeenconfirmedover5years
in the Treatment of Peripheral Osteoporosis study [16].
Many factors contribute to bone fragility that leads to
osteoporotic fractures [31]. One important mechanism is the
progressive net loss of bone due to a greater degree of bone
resorption than formation at focal remodeling sites, leading
to an overall deficit in bone formation in later adult life. In
postmenopausal women, the rate of net bone loss is
accelerated by an increase in the intensity of bone remodel-
ing in response to reduced estrogen levels. Antiresorptive
agents such as bisphosphonates and raloxifene reduce the
rate of bone remodeling, reflected in decreases in markers of
both bone formation and bone resorption [32, 33]. Strontium
ranelate appears to have a different mode of operation. In
various animal models, strontium ranelate has been shown to
prevent bone loss by increasing bone formation and
decreasing bone resorption [34]. These in vivo results were
consistent with in vitro data where strontium ranelate has
been shown to reduce bone resorption by osteoclasts and to
stimulate bone formation by osteoblasts [34, 35]. It has been
demonstrated in vitro that strontium ranelate is an agonist of
the CaR and is able to stimulate the replication of osteoblasts
through the activation of CaR [36]. CaR is one of the major
molecular determinants involved in controlling the cations
concentration through regulation of PTH [37]. The slight
decrease in serum calcium and PTH in association with a
slight increase in blood phosphorus observed in this study is
in agreement with an action mediated through the CaR in
postmenopausal women.
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ranelate, analysis of serum markers of bone metabolism
over the first 3 and 4 years of the SOTI study showed that
strontium ranelate treatment was associated with a small but
significant increase in bALP and a significant decrease in
sCTX, relative to placebo [12]. Following treatment
withdrawal, results obtained were in agreement with this
dual mode of action as they show a significant decrease in
bALP and an increase in sCTX. These changes are already
observed 3 months after treatment discontinuation, suggest-
ing a relatively rapid release of strontium from bone.
In the present analysis, patients who continued on
strontium ranelate in the main treatment period and in the
treatment-switch period showed a progressive increase in
BMD throughout the entire 5-year period. The increase in
lumbar BMD from M48 to end in the SR/SR group (1.2±
5.8%) is clinically significantly smaller than in the placebo/
SR group (5.3±7.3%). Increase of bone density with
strontium ranelate may be due to different effects: increase
in bone mass, increase in the degree of mineralization, or
artifactual increase of BMD due to the presence of
strontium in bone. Studies on bone biopsies have demon-
strated that the degree of mineralization is not modified
compared to placebo after 3 years of treatment [38].
Regarding the bone strontium content, it has been demon-
strated that bone strontium content reached a plateau after
3 years of treatment [39]. This plateau might explain at
least partly the smaller increase in BMD after 4 years of
treatment compared to the first year of treatment and
suggested that strontium ranelate continue to increase bone
mass despite the plateau observed in bone strontium
content. Furthermore, a strong relationship between the
increase in BMD and a subsequent reduction of the risk to
have a new vertebral or hip fracture have been demonstrat-
ed in strontium ranelate-treated patients indicating that
BMD may be of interest to monitor those patients for
3 years [40, 41]. After treatment withdrawal, patients who
switched to placebo at 4 years experienced a significant
reduction in BMD, showing effects of strontium ranelate to
be progressively reversible and reflecting clearance of
strontium from bone. Decrease observed after treatment
cessation is also suggesting that BMD may be followed up
after a treatment with strontium ranelate.
After 3 years, strontium ranelate treatment was associ-
ated with significant beneficial effect on QoL, relative to
placebo, assessed by QUALIOST®, a validated disease-
targeted QoL instrument [24, 25, 42]. These results are
confirmed after 4 years of treatment: Both the emotional
and physical components of the global QUALIOST® score
were improved in comparison to placebo (p=0.012 and p=
0.034, respectively).
Relative to baseline, placebo-treated patients showed an
initial improvement in global QUALIOST® score at the 6-
month assessment, followed by a progressive worsening
throughout the remainder of the 4-year treatment period, with
scores at the last four assessments worse than at baseline. The
strontium ranelate group showed significant benefits on QoL,
relative to baseline, atall assessments, indicating that strontium
ranelate prevented or delayed the progressive worsening of
QoL with time seen in placebo-treated osteoporotic women.
The magnitude of the difference in the change of
QUALIOST® total score from baseline to last assessment
between the strontium ranelate and placebo groups was
clinically relevant as it reached approximately 2.0; this may
be compared with the difference of 1.38 observed using the
same instrument between patients with one new osteoporotic
fractureand patientswithout new fracture[24]. It is important
to note that these changes represent predominantly the long-
term effects of fractures on QoL; soon after the occurrence of
fracture, the impact on QoL may be larger.
Although the impact of osteoporotic fractures on QoL has
been explored in several studies, there have been relatively
few studies evaluating the effects of anti-osteoporotic drugs
on QoL. One year of treatment with alendronate or calcitonin
significantly reduced pain and improved QoL compared with
calcium supplementation in a study of 151 patients [43].
Raloxifene treatment had no significant effect, relative to
placebo, on QoL over 3 years [44]. A meta-analysis of five
studies indicated that teriparatide treatment reduced the risk
of new or worsening back pain, although wider QoL was not
evaluated [45]. To our knowledge, the present study is the
first large, long-term randomized study to demonstrate
preplanned beneficial effects of an anti-osteoporotic drug
on back pain and QoL.
In conclusion, in this 5-year randomized trial in
postmenopausal women with osteoporosis, long-term treat-
ment with strontium ranelate 2 g/day was associated with a
33% reduction in the risk of vertebral fractures, relative to
placebo, over a 4-year treatment period. The reduction in
fractures was accompanied by a significant improvement in
QoL and increase in the number of patients free of back
pain. BMD increased progressively throughout 4 and 5
years of strontium ranelate treatment, and began to decline
in those patients switched from strontium ranelate to
placebo at 4 years. This decrease in BMD following
treatment cessation may have reflected strontium elimina-
tion from bone. Strontium ranelate represents an effective
first-line intervention for long-term treatment in postmen-
opausal women with osteoporosis.
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